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ABSTRACT 
The synthesis of diverse 3-dimensional libraries has become of paramount importance for obtaining better leads 
for drug discovery. Such libraries are predicted to fare better than traditional compound collections in 
phenotypic screens and against difficult targets. Herein we report the diversity-oriented synthesis (DOS) of a 
compound library using rhodium carbenoid chemistry to access structurally diverse, 3-dimensional molecules, 
and show that they access biologically relevant areas of chemical space using cheminformatic analysis. High 
content screening (HCS) of this library for anti-mitotic activity, followed by chemical modification identified 
‘Dosabulin’, which causes mitotic arrest and cancer cell death by apoptosis. Its mechanism of action is 
determined to be microtubule depolymerization, and the compound is shown to not significantly affect 
Vinblastine binding to tubulin, however experiments suggest binding to a site vicinal or allosteric to Colchicine. 
This work validates the combination of DOS and phenotypic screening as a strategy for the discovery of 
biologically relevant chemical entities.  
 
INTRODUCTION 
Diversity-oriented synthesis (DOS) aims to synthesize libraries of structurally complex and functionally diverse 
small molecules in an efficient manner
1, 2
. Biomolecules interact with each other in a three dimensional 
environment, and consequently, functional diversity is directly associated with the three dimensional chemical 
information the surface of a small molecule presents when interacting with macromolecules, such as protein.  
The last decade has witnessed the emergence of several distinct DOS strategies for the construction of 
chemically diverse libraries
3-5
.  One such method, the reagent-based approach
3
, involves synthesizing one or 
more densely functionalized molecules, which can subsequently be transformed into diverse molecular 
scaffolds.  These molecules can be reacted selectively with a wide variety of reagents, providing access to an 
array of distinct molecular frameworks. Alternatively, a single pluripotent functional group can be exploited by 
subjecting it to a wide variety of reaction conditions thereby enabling the synthesis of multiple molecular 
skeletons.  Carbenoid chemistry offers exciting opportunities for DOS applications, particularly in the context of 
the reagent-based approach.  A wealth of distinct reactions can be performed using carbenoid chemistry,
6
 and its 
applicability to library construction, was recently exemplified by Panek and co-workers
7
. In addition to scaffold 
diversity, increasing carbogenic sp
3
 content and the number of stereocentres has been suggested to enhance 
selectivity and potency for a given target, and increase hit rate across several targets from a single library
8
. 
Furthermore, increasing sp
3
 count correlates favourably with decreasing clinical toxicity
9
, and decreasing 
aromatic ring count is likely to produce less compound attrition in drug discovery
10
. It is important that these 
considerations are implemented in DOS strategies and that effective methods are developed to enable the 
efficient synthesis of structurally diverse compound collections. 
Phenotypic screening is an expedient mechanism for identifying small molecules that perturb 
biological function.  It provides an efficient way to evaluate the biological activity of a compound collection 
against a wide variety of molecular targets
11
. Recently it has also been established that the vast majority of first-
in-class drugs were identified by phenotypic screening
12
. Our group and others have successfully implemented 
this approach in combination with DOS to discover novel small molecule modulators of biological function
13
. In 
2008, we discovered gemmacin, a small molecule with similar potency to clinically used antibiotics and 
improved activity against resistant bacterial strains
14
. Other groups have also used this approach effectively; 
some notable examples include the discovery of the novel Hedgehog pathway modulator robotnikinin
15
, and 
compounds with interesting anti-malarial properties
16
. Another related approach termed biology-oriented 
synthesis (BIOS), has also led to the identification of many useful tool compounds from phenotypic screens
17-19
. 
Phenotypic screening has been used effectively to discover new anti-mitotics
20, 21
. Whilst several clinically used 
anti-mitotics exist, they often suffer from administration or resistance problems
22, 23
. Additionally, they are 
mostly derived from natural products, making chemical modification difficult. Therefore there is an increased 
requirement for new compounds that cause mitotic arrest.  
Herein, we report the efficient synthesis of a functionally diverse compound collection, using rhodium 
carbenoid chemistry in a reagent-based approach. These molecules display a high sp
3
 content and access 
biologically relevant areas of chemical space. Furthermore, using phenotypic high content screening, we present 
the biological evaluation of these compounds using an assay detecting the induction of mitotic arrest. We 
present one hit series, which induces mitotic arrest by depolymerising microtubules and binds in a site vicinal or 
allosteric to Colchicine.  
 
RESULTS 
 
Library Synthesis 
To synthesize the library, we developed a reagent-based DOS approach employing rhodium carbenoid chemistry 
to produce pluripotent substrates, from which a range of structurally diverse small molecules could be regio- and 
diastereo-selectively synthesized.  To this end, we envisaged the use of phenyldiazo ester compounds (1 and 12) 
as highly functionalized substrates from which a structurally complex compound collection could be constructed 
(Figures 1 and 2).  Rhodium catalyzed cyclopropanation of compound 1, which was obtained according to 
literature precedent
24
, with a range of unsaturated compounds led to the formation of densely functionalized 
molecular frameworks (Figure 1).  Diastereoselective reaction of 1 with terminal alkynes and alkenes provided 
cyclopropenes and cyclopropanes respectively in good yields and complete diastereocontrol for 4 (Figure 1, 
pathways a and b)
25
. Cyclopropene 2 allowed further diversification by palladium catalyzed C-H activation, 
coupling 2 with p-nitroiodobenzene using Heck-type reaction conditions to yield 3
26
. The generation of 
functionality variants was accomplished by the reaction of 1 with various allenes, affording the corresponding 
cyclopropanes with exocyclic alkenes (5-6), which could be converted to the lactones (7-8) via iodo-
lactonisation
27
. The remaining iodide was then successfully removed by radical de-iodination to give 9 and 10, 
completing a subset of the library based on 1. 
Encouraged by the scope of complexity generating methodology accessible via rhodium (II) catalyzed 
carbenoid chemistry, we decided to synthesize the styryl diazoester derivatives 11 and 12. Davies et al. 
demonstrated the ability of 11 to undergo tandem cyclopropanation-Cope rearrangement reactions, resulting in 
the diastereoselective formation of highly functionalized heptadienes
28
. We hypothesized that the synthesis of a 
bicyclo[3.2.1]octadiene scaffold from a styryl diazoester containing an ortho-bromo aryl functionality (as in 
compound 12), would furnish a bicyclic construct poised for further diversification.  Adorned with reactive 
functionally, intermediate 12 could be subjected to a variety of diversity generating reactions, thus providing a 
library of skeletally diverse small molecules containing multiple stereocentres. Taking precedent from the 
described synthesis of 11,
 
compound 12 was initially synthesized via a Wittig olefination of 
bromobenzaldehyde, followed by esterification and diazo formation (Supplementary Figure 1). However, the 
Wittig reaction provided a mixture of (E) and (Z) stereoisomers, presumably due to steric hindrance of the 
bromo substituent. Optimization of the synthetic route followed; treating 2-bromophenyl acetaldehyde with 
malonic acid in Hünigs base provided the Knoevenagel condensation product. Subsequent esterification 
delivered a mixture of regioisomers (Supplementary Scheme S1b), which was readily converted to the desired 
diazo compound 12 as a single (E) stereo- and regioisomer. 
 Intermediate 12 was subjected to a cyclopropanation-Cope rearrangement according to the procedure 
developed by Davies et al. to provide the highly functionalized key intermediate 14 in good yield (Figure 2)
28
. 
This reaction delivered three new stereocentres with complete diastereocontrol, thereby enabling further 
diversification via stereocontrolled reactions. The presence of both an electron deficient and an electron neutral 
olefin in the bicyclic system, coupled with the proximal aryl bromide and a carboxylic acid ester in the 
backbone of compound 14, afforded the opportunity to regioselectively modify the scaffold in a multi-
directional approach. Our exploration of the chemical space around scaffold 14 began with a stereoselective 
epoxidation reaction, resulting in the formation of epoxide 15 on the less hindered face in excellent yield. The 
relative stereochemistry of this compound was confirmed by NOESY experiments, which showed no interaction 
between the methine epoxide protons and those of the fused ring bridgehead. Regio- and stereoselective 
dihydroxylation of the electron neutral alkene was performed under Upjohn conditions, using osmium tetroxide, 
thereby providing the chiral cis-diol 16, containing 5 contiguous stereocentres, and a further molecular construct 
poised for diversification. The stereochemical relationship of the two new sterocentres confirmed that the 
dihydroxylation reaction occurs selectively from the less hindered face of heptadiene 14. Reacting diol 16, with 
commercial aldehydes and ketones under acidic conditions provided acetals 17-21, in good yield. Finally, 
sulfoxide 22, which comprises six chiral centres was readily synthesized as a 3:1 mixture of diastereomers, by 
reacting 16 with thionyl chloride.  
The production of new ring systems was achieved by subjecting 14 to one-pot dihydroxylation and 
oxidative cleavage methodology developed by Nicolaou
29
 using (diacetoxyiodo)benzene, followed by reductive 
amination conditions. The use of dimethylamine enables the synthesis of the highly functionalized cyclohexene 
23, however more interesting heterocyclic scaffolds were accessed when primary amines were utilized, as a 
consequence of double reductive amination reactions. Thus 6-6 fused ring frameworks, with varied appendage 
diversity were obtained (Figure 2, compounds 24-31). We observed that the reducing agent sodium 
triacetoxyborohydride was essential for this process, to selectively reduce the imines formed in the reaction in 
the presence of the aldehyde functionality. The crystal structure of 31 confirmed the expected relative 
stereochemistry, which had been maintained throughout this three-step, one-pot process. To further increase the 
diversity of the library, the dialdehyde obtained via the dihydroxylation/oxidative cleavage of 14 described 
above, was selectively reduced to the corresponding diol and spontaneously cyclized through a ring closing 
transesterification reaction, yielding the novel lactone scaffold 32 in just one synthetic step. 
Building block 14 was viewed as a perfect substrate for molecular decoration and adornment in 
transition metal catalyzed reactions. The electron neutral alkene was amenable to ring opening/cross metathesis 
(ROCM) with terminal olefins, providing newly functionalized cyclohexene structures 33-35. On the other 
hand, the ortho-bromo aryl substituent present in 14 provided a functional handle for cross-coupling reactions, 
introducing appendage diversity around the core scaffold. A series of Suzuki couplings to form new biaryl bonds 
were also performed. Although the yields for this process were poor, predominantly due to proto-debromination 
and the formation of compound 13, sufficient material for biological evaluation was in hand, so we decided to 
forgo optimization of this process at that stage. In total a library of 35 compounds with 10 distinct molecular 
scaffolds was synthesized (Supplementary Figure 2), comprising complex fused ring systems of varying size 
and a multiplicity of stereocenters. 
 
Cheminformatic Analysis  
To computationally assess its structural diversity, we carried out a comparative statistical analysis of a set of 
molecular descriptors for our DOS library and two reference compound collections, comprising 40 top-selling 
brand-name drugs and 60 diverse natural products
30,31
. Principle component analysis (PCA) utilizes a defined set 
of molecular descriptors, such as physicochemical properties, to represent each component compound as a 
vector in n-dimensional space.  n-Dimensional vectors can then be reduced to 2-dimensional vectors by an 
orthogonal transformation, and re-plotted as a scatter plot, thereby providing an illustrative representation of the 
diversity of the compound collection.  Fifteen physicochemical properties (Supplementary Table 1) of the 
compounds were analyzed using the molecular operating environment (MOE) software. The first three principal 
components account for 87% of the dataset variance and are represented in 2D plots (Figures 3a-c and 
Supplementary Table 2).  As seen in Figures 3a-c, our DOS library overlaps considerably with the chemical 
space explored by the top-selling drugs, indicating the potential drug-likeness of the library and possibly 
intimating that it should access biologically relevant areas of chemical space. Examination of the component 
loadings (Supplementary Table 3) shows that increases in ring count and number of nitrogen and oxygen atoms 
shift molecules in the positive direction along the PC1 axes, whereas molecules with high hydrophobicity and 
ring count are driven in the positive direction along the PC2 axes. Important contributors to the variance in PC3 
are nitrogen atom, aromatic atom and ring count, all of which an increase leads to a positive shift along the PC3 
axes. These suggest that ring count is an important property contributing to the overlap between our DOS 
compounds and the drug library. 
We also compared the degree of shape diversity in our DOS library with the two reference sets of 
compounds. Based on the lowest-energy conformations of the compounds, normalized ratios of principal 
moment of inertia (PMI) were calculated and plotted on a triangular graph
32
. The PMI plot obtained (Figure 3d) 
illustrates the shape diversity of the compounds, with its vertices representing the three extremes of molecular 
shape (rod, disc and sphere). The drug reference set predominantly contains rod-like shapes with some disc-like 
character while the natural products exhibit considerably higher shape diversity. A very good level of shape 
diversity was achieved by the DOS library. We performed a Kolmogorov-Smirnov test to evaluate whether there 
is a significant difference between the distances of the vertices to the drugs and DOS library compounds on the 
PMI plot
33
. The results are not significant for distances to the disc corner (p = 0.217). However, the two libraries 
are significantly different in terms of distances to the other two canonical PMI shapes, with the drugs tending 
towards the rod corner (p = 0.027) and the DOS compounds tending towards the spherical corner (p = 0.002). 
This suggests that the DOS compounds contain scaffolds that are drug-like but are more spherical and 3-
dimensional in character than the drugs. This is particularly important, as the lack of 3-dimensionality and low 
sp
3
 carbon content is considered to be one of the main reasons why combinatorial screening collections fail to 
deliver hits against challenging targets such as protein-protein interactions (PPIs) or protein-DNA interactions
34
. 
 
Biological Evaluation 
Anti-mitotic compounds are already used clinically, and this target class still holds great promise for anti-cancer 
therapy. However resistance and administration problems have increased the requirement for new therapies
22, 23
. 
One avenue to identify anti-mitotic compound is by conducting a phenotypic screen for mitotic arrest. Therefore 
we focused our attention on a high content screen using automated microscopy
35, 36
. The screen was performed 
using U2OS osteosarcoma cells, which were incubated for 20 hours with all of the library compounds, stained 
for the mitotic marker phospho-Histone H3 and imaged on a Cellomics Arrayscan high content microscope. 
Image analysis allowed us to detect the percentage of cells arrested in mitosis following compound treatment. 
The assay utilized nocodazole as a positive control and had a Z factor of 0.77, indicating an excellent assay, 
particularly for a phenotypic screen (Supplementary Figure 3)
37
. All compounds were soluble at the assay 
concentration (50 µM) and most compounds re-screened were soluble up to 100 µM. It was encouraging to see 
that two molecules (37 and 38) from the original library showed mitotic arrest, with EC50 values in the single-
digit micromolar range (Table 1). This is particularly significant as the library was not biased towards a 
particular type of target class. An additional advantage of the high content screening approach is that one is able 
to identify compounds that perturb cell function without affecting the primary assay read-out. For example, we 
were able to identify two compounds (24 and 26) that caused a decrease in cell viability with GI50's of 21 and 14 
µM respectively (Supplementary Figure 4) which did not induce a mitotic arrest. Whilst we do not know the 
targets of these molecules, their identification is a further testament to the ability of DOS to produce potentially 
useful scaffolds.   
 
Analogue Synthesis 
In the mitotic index assay, the most potent compound (38) from the primary screen gave a large (35-40%) 
mitotic arrest, which resulted in tumor cell death in a 72-hour cell viability assay (Table 1). Encouraged by this 
promising result, we sought a synthetic route that was higher yielding for analogue synthesis. It was envisaged 
that reducing the electron neutral double bond would reduce the risk of side reactions in the subsequent Suzuki 
coupling. Moreover, biological evaluation of the reduced products would provide some structural-activity 
relationship information about the chemotype as well as reduce the possibility of further biochemical reactions. 
A new synthetic route to the reduced products was devised (Figure 4) to achieve the desired cycloheptene. 
Diimide reduction of intermediate 14 followed by Suzuki coupling with the appropriate boronic acids provided 
the desired compounds 40 and 41 in good yield.  Both analogues gave a mitotic arrest in U2OS cells. In fact, 
comparing compound 38 with its partially saturated analogue 41 we observed a two-fold increase in potency. 
Treatment with 40 and 41 also resulted in growth inhibition in the low micromolar range over a period of 72 
hours (Table 1). Given that all compounds were produced as racemates, we predicted that the anti-mitotic 
activity was likely to reside in just one of the enantiomers. Separation of both enantiomers of Dosabulin by 
preparative chiral HPLC and subsequent re-testing, revealed that all the activity resided in the (1R,4S,5S)- 
enantiomer, which will henceforth be referred to as (S)-41 (Table 1 and Figure 5a, b, and c). In fact, this enabled 
the use of the (1S,4R,5R)- enantiomer (R)-41 as a negative control. We were then able to show that (S)-41 
treated cells died through apoptosis (Supplementary Figure S5)
38
 whilst cells treated with (R)-41 did not. At this 
stage we focused our attention on identifying the mechanism of action of these compounds.  
 
Target Identification 
Identification of the targets from a phenotypic screen can often be the rate-limiting step
39
. However, careful 
observation of the phenotype may sometimes offer clues on what the target may be, allowing more informed 
experiments to be conducted
40
. Confocal microscopy was used to look at the key mitotic protein, tubulin, for 
this purpose. This revealed that the tubulin network was heavily disrupted upon treatment with (S)-41 compared 
to the DMSO control, which suggested that the compound may be targeting tubulin itself (Figure 6a, 
Supplementary Figure 6). This phenotype was recapitulated by nocodazole, a known tubulin depolymerizer. 
This result was not altogether unexpected, given that several clinically used anti-mitotics target tubulin 
polymerization dynamics
41
. Using an in vitro tubulin polymerization assay it was established that (S)-41 acts as 
a tubulin depolymerizing agent,
42
 similar to our positive control nocodazole (Figure 6b). This compound was 
subsequently termed ‘Dosabulin’, for DOS tubulin inhibitor. The inactive (R)-enantiomer did not show any 
tubulin depolymerization ability. It is widely accepted that several small molecule binding sites exist on 
tubulin
43
. For example, Vinblastine binds the -tubulin subunit, whilst Colchicine binds at the / interface. 
Additional compounds targeting tubulin dynamics exist, for which the binding site has yet to be fully elucidated, 
such as Noscapine and Peloruside. To establish whether (S)-Dosabulin bound in either of the established tubulin 
binding sites which cause depolymerisation, two in vitro fluorescence based assays monitoring displacement of 
Colchicine or Vinblastine from tubulin by (S)-Dosabulin were used (Figure 6c and d). To monitor binding at the 
Vinblastine site, a fluorescence polarization (FP) assay was developed. Using commercially available 
fluorescently tagged Vinblastine it was shown that polarization increases upon tubulin binding (Supplementary 
Figure 7). Once the optimal tubulin concentration for a sufficiently large assay window was selected, (S)-
Dosabulin was screened for its ability to inhibit tubulin at this site. (S)-Dosabulin did not significantly affect the 
binding of fluorescently labeled Vinblastine to tubulin in this FP assay (Figure 6c and Supplementary Figure 8). 
To determine whether (S)-Dosabulin was able to bind in the Colchicine site, the change in intrinsic Colchicine 
fluorescence when bound to tubulin was measured. A time course experiment as carried out to observe whether 
(S)-Dosabulin was able to displace Colchicine from tubulin (Supplementary Figure 9). In fact, treatment with 
(S)-Dosabulin resulted in a time- and dose-dependent inhibition. However, incomplete inhibition was seen 
compared to Nocodazole (Figure 6d). This suggests that (S)-Dosabulin may not directly displace Colchicine, but 
rather bind to a site vicinal or allosteric to it, resulting in a decrease of its binding affinity for tubulin.  
 
 DISCUSSION 
In this study we report the synthesis and biological evaluation of a DOS library constructed using rhodium (II) 
catalyzed carbenoid chemistry to access key pluripotent intermediates. A total of 35 complex and structurally 
diverse compounds were synthesized. Biological screening of this collection in a high content microscopy-based 
approach revealed two compounds that arrested cells in mitosis. Following some structural modifications we 
identified Dosabulin, a novel small molecule that arrested cells in mitosis by depolymerizing microtubules. It 
causes a dose-dependent displacement of Colchicine from tubulin, however no complete disruption of the 
interaction is observed. This suggests that it binds in a site in the vicinity of, or allosteric to Colchicine.   (S)-
Dosabulin causes cell death by apoptosis in U2oS osteosarcoma cells at sub-micromolar concentrations. With 
new tubulin binding compounds such as eribulin recently being approved
44
, and existing therapies suffering 
from administration and resistance problems
22
, new anti-mitotics targeting tubulin are required
23
. We hope that 
Dosabulin and related studies may spur new drug discovery efforts in this field. To further assess the utility of 
this library, further biological screens for antibacterial activity and inhibition of selected protein-protein 
interactions are ongoing. This work validates DOS in combination with phenotypic screening as an effective 
strategy for the identification of new biologically relevant chemical entities.  Adoption of this approach on a 
wide scale is likely to prove fruitful in the context of chemical genetics and drug discovery. 
 
METHODS 
 
Chemical Synthesis 
Compounds were synthesized according to procedures specified in Supplementary Note 1 and Supplementary 
Methods. X-ray crystallographic data and images are reported in Supplementary Figures 10-12 and 
Supplementary Tables 1-13. For 
1
H and 
13
C NMR spectra of compounds reported see Supplementary Figures 
13-45.  
 
Principal component analysis 
Principal component analysis (PCA) was carried out using the Molecular Operating Environment (MOE) 
software package
45
. A total of 15 physicochemical properties (Supplementary Table 14) were obtained for 
established reference sets of 40 top-selling brand-name drugs and 60 diverse natural products and 36 DOS 
library members
30
. The summary of the contribution of each principal component is shown in Supplementary 
Table 15 and the component loadings are shown in Supplementary Table 16. The first three principal 
components account for 86.9 % of the variance in the dataset and were used to generate Figure 3a-c. 
 
Principal moment of inertia calculations 
We compared the molecular shape diversity of our DOS library with the reference sets of 100 compounds used 
in the PCA. The stochastic conformational search algorithm in the MOE software package was used to generate 
3D conformers for each compound. The MMFF94x force field was used with the generalized Born solvation 
model for the minimizations. Sampling and minimization parameters were implemented as follows: 
 
Stochastic Search Limit: 7 
Refinement Conformation Limit: 300 
Stochastic Search Failure Limit: 100 
Stochastic Search Iteration Limit: 1000 
Energy Minimization Iteration Limit: 200 
Energy Minimization Gradient Test: 0.01 
 
Only the conformer with the lowest energy was retained for principal moment of inertia (PMI) calculations in 
each conformational sampling run. Normalized PMI ratios (I1/I3 and I2/I3) of these conformers were obtained 
from MOE and then plotted on a triangular graph, with the coordinates (0,1), (0.5,0.5) and (1,1) representing a 
perfect rod, disc and sphere respectively (Figure 3d). 
 
High Content Analysis – Mitotic Index 
HCA was performed using an Arrayscan II HCS reader and integrated software from Cellomics. U2oS 
osteosarcoma cells (ATCC) were seeded in a NUNC clear flat-bottomed 96-well plate at 10,000/well in a total 
of 100 μL. They were incubated at 37 ºC overnight. Cells were then treated with compounds (25 μL) to give the 
appropriate concentration. Cells were then incubated at 37 ºC for 20 h. 50 μL 12.5 % formaldehyde was added 
to each well. This was incubated at RT for 10 min, before the formaldehyde was gently removed. 100 μL/well 
permeabilization buffer (PB, contains PBS + 0.1% Triton X-100), was then added to each well, incubating for 
10 min. PB was removed and wells were washed with 100 μL/well blocking buffer (BB, contains PBS + 1% 
BSA). BB was removed and 50 μL/well of primary antibody solution (anti-pH3 (S10), Abcam, ab5176, 1:2000) 
was added. Plates were incubated for 1 h at room temperature. The antibody was removed and wells washed 
with 2 x 100 µL/well BB. BB was removed and 50 μL/well of secondary antibody solution containing Hoechst 
(Invitrogen, H3570, 1:2500) and AlexaFluor 488 Goat anti-rabbit IgG (Invitrogen, A11034) was added. Plates 
were incubated at RT for 1 h in the dark. Secondary antibody solution was removed and plates washed with 2 x 
100 μL BB. The BB was then removed and 100 μL PBS/well were added. The plates were sealed with opaque 
film and images taken on a 20x 0.4 NA objective. Data was analysed on Cellomics Arrayscan software using the 
Target Activation v4 protocol. Critical output features are: ValidObjectCount and %Responder_AvgIntenCh2. 
EC50 data was calculated using Prism (Graphpad) and is an average of three independent experiments conducted 
in triplicate. 
 
Sulforhodamine B colorimetric assay for cytotoxicity screening  
This assay was conducted according to literarure procedure
46
. U2oS cells were seeded at 4000 cells/well in 180 
µL and incubated for 20 h at 37 °C. Compounds were then added in 20 µL to give the desired concentrations. 
After incubation for 72 h at 37 C the medium was removed by aspiration, and 100 µL of 1% TCA solution was 
added. This was incubated for 1 h and then removed. The plates were washed 4 x with tap water and the plates 
were allowed to air dry at RT. 100 µL of a 0.057 % wt/vol solution of Sulforhodamine B (Sigma Aldrich) were 
added to each well, incubating for 30 min. The plates were then washed quickly with 4 x 100 µL of acetic acid 
solution (1%) and then air-dried. 200 µL of TRIS buffer (10 mM, pH 8.0) was added to each well to resolubilise 
the dye. The plates were then read at 510 nm on a Infinite® M200 plate reader (Tecan, Austria). GI50 data was 
calculated using Prism (Graphpad) and is an average of three independent experiments conducted in triplicate. 
 
Confocal Microscopy 
200,000 U2oS cells were seeded on coverslips in 2 mL medium in a six-well plate and incubated at 37 °C 
overnight. Compounds were added in DMSO to the appropriate concentration and the cells were incubated for 
16 hours. The medium was then aspirated and the cells were then fixed in 1 mL PBS containing 4% para-
formaldehyde for 10 min. Cells were permeabilised in PBS containing 0.1% Triton-X (PBS-T) for 10 min and 
then washed with 1 mL PBS containing 1% BSA (PBS-BSA). Tubulin was visualized using an -tubulin 
antibody (1:1000) in 500 µL for 2 h. The primary antibody was then removed and the cells were washed with 1 
mL PBS-BSA three times. Alexafluor-488 conjugated goat anti-rabbit (Invitrogen, A11034) secondary antibody 
was then added in 500 µL PBS-BSA for 1 h. The secondary antibody was removed and cells were washed twice 
with PBS-BSA and once with PBS. The coverslips were mounted on slides with mounting medium containing 
DAPI and imaged on a Zeiss LSM-510 confocal microscope with a 100X objective.  
 
Tubulin in vitro polymerization assay 
This assay was performed according to the literature procedure
42
. Compounds were dissolved in 10 μL 1X 
General Tubulin buffer (PEM) containing 80 mM Na-PIPES pH 6.9, 1 mM MgCl2 and 1 mM EGTA and added 
to wells in a 96-well plate. The tubulin solution was prepared by dissolving porcine α/β-tubulin (> 99% pure, 
Cytoskeleton, USA) in 1X General Tubulin Buffer containing 10% glycerol, and 1 mM GTP. 100 µL of this 
tubulin solution (3.0 mg/mL) was added to the compound solutions or the control prewarmed in the 96-well 
plate at 37 °C. Tubulin polymerization was monitored over 60 min by reading the increase in fluorescence at 
ex/em 340/460 nm in the Infinite® M200 plate reader (Tecan, Austria). 
 
Colchicine competition assay  
3 μM tubulin was incubated with 3 μM colchicine (Sigma Aldrich) and the appropriate concentrations of (S)-
Dosabulin or nocodazole in PEM buffer at 37 °C for a total volume of 45 μL/well in black 384-well plates 
(Corning). Fluorescence readings (ex/em 365/435 nm) were taken every 15 min for 1.5 h using Infinite® M200 
plate reader (Tecan, Austria). Fluorescence values were normalized to the DMSO control. 
 
Vinblastine competition assay 
Tubulin (2 μM) and BODIPY-FL-vinblastine (2 μM, Invitrogen) in PEM buffer were incubated with different 
concentrations of (S)-Dosabulin, or vinblastine sulfate (Alfa Aesar) for 20 min at RT in a total volume of 45 
μL/well. Fluorescence polarization readings were performed in black 384 well plates using a PHERASTAR 
plate reader (excitation/emission wavelengths 485/520 nm). FP values were normalized to the DMSO control. 
 
Accession Codes 
The X-ray crystallographic coordinates for structures reported in this Article have been deposited at the 
Cambridge Crystallographic Data Centre (CCDC), under deposition numbers CCDC 936205, 936206, and 
936208. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre 
via www.ccdc.cam.ac.uk/data_request/cif. 
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FIGURES 
 
Figure 1. Synthetic scheme of DOS library subset based on 1; (a) Phenylacetylene, Rh2(OAc)4 (1 mol%), CH2Cl2; (b) p-nitroiodobenzene, 
Pd(OAc)2 (10 mol%), K2CO3, DMF; (c) styrene, Rh2(OAc)4 (1 mol%), CH2Cl2; (d) undeca1,2diene or propa-1,2-dien-1-ylcyclohexane, 
Rh2(OAc)4 (1 mol%), CH2Cl2; (e) N-iodosuccinimide, MeCN-H2O (2:1), 50 C; (f) Bu3SnH, AIBN, PhH, 80 C;  
 
 
 
 
Figure 2. Library synthesis from key building block 14; (a) cyclopentadiene, Rh2(OAc)4 (1 mol%), CH2Cl2; (b) m-CPBA, CH2Cl2; (c) OsO4 
(2.5 mol%), NMO, acetone-H2O (9:1); (d) aldehyde/ketone, CSA (10 mol%), 3Å molecular sieves, CH2Cl2; (e) SOCl2, CH2Cl2; (f) 2,6-
lutidine, NMO, OsO4 (2.5 mol%), PhI(OAc)2, acetone-H2O (10:1), then dimethylamine, NaBH(OAc)3, CH2Cl2; (g) 2,6-lutidine, NMO, OsO4 
(2.5 mol%), PhI(OAc)2, acetone-H2O (10:1), then primary amine, NaBH(OAc)3, CH2Cl2; (h) 2,6-lutidine, NMO, OsO4 (2.5 mol%), 
PhI(OAc)2, acetone-H2O (10:1), then NaBH4, MeOH; (i) alkene, Hoveyda-Grubbs (II) catalyst (10 mol%), ethylene, PhMe, 100 C; (j) 
Pd(OAc)2 (10 mol%), PPh3 (15 mol%), 2N K2CO3, PhMe, 90 C; 
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Figure 3. PCA and PMI plots of 35 DOS library compounds (red), 40 top-selling brand-name drugs (green) and 60 diverse natural products 
(blue); (a) PCA plot of PC1 versus PC2; (b) PCA plot of PC1 versus PC3; (c) PCA plot of PC3 versus PC2; (d) PMI plot illustrating the 
molecular shape diversity of the DOS library and lowest-energy conformations of three representative DOS library members. 
 
  
Figure 4. Synthetic route to new analogues of anti-mitotic compounds; (a) CuCl2, hydrazine hydrate, EtOH; (b) ArB(OH)2, Pd(PPh3)4 (5 
mol%), 2N K2CO3, dioxane, 120 C, W. 
 
Figure 5. Biological screening results of the DOS library; (a) Representative image output from the phenotypic screen, highlighting the 
increase in mitotic cells for those treated with the positive control nocodazole and (S)-Dosabulin. U2oS cells were stained with Hoechst 
(blue) and a phospho-Histone H3 (pH3) antibody (green). Data was collected on a cellomics arrayscan high content microscope with a 20X 
planfluor objective; scale bar: 70 µm; (b) Representative mitotic index assay data in U2oS cells for racemic Dosabulin and its purified 
enantiomers. Data points are mean  s.e.m. of an experiment conducted in triplicate. CPD = compound; (c) Growth inhibition curves in 
U2oS cells assessed by sulforhodamine B assay for Dosabulin and its purified enantiomers.  Cells were treated with compounds for 72 h, 
before fixing and treating with the protein dye. Data points are mean  s.e.m. of an experiment conducted in triplicate; 
 
 
 
Figure 6. Target identification of Dosabulin: (a) Confocal microscopy in U2oS cells of both enantiomers of Dosabulin show that the (S)-
enantiomer disrupts the tubulin network in interphase cells, similarly to nocodazole, whilst the (R)-enantiomer does not. U2oS cells were 
stained with DAPI (blue) and an -tubulin specific antibody (green). Scale bar: 15 µm; (b) in vitro tubulin polymerization data shows that 
(S)-Dosabulin causes a decrease in tubulin polymerization, confirming this as a mechanism of action. Porcine brain tubulin (3 mg/mL) kept 
at 4 C was incubated with test compounds for 60 min at 37 C. Compound concentrations: (S)-Dosabulin and (R)-Dosabulin used at 20 µM, 
nocodazole at 5 µM. OD = Optical Density; (c) fluorescence polarization (FP) data using FL-BODIPY-Vinblastine (2 µM) as a tracer shows 
that (S)-Dosabulin does not bind tubulin in the Vinblastine site. FP values were normalized to the DMSO control, and data points are mean  
s.e.m. of an experiment conducted in triplicate (ex/em wavelengths 485/520). CPD = compound; (d) fluorescence intensity (F) 
measurements using Colchicine show that (S)-Dosabulin (red) causes a dose-dependent decrease in fluorescence without completely 
inhibiting the interaction and thus is likely to bind in the vicinity or allosterically to Colchicine. F values were normalized to the DMSO 
control and data points are mean  s.e.m. of an experiment conducted in triplicate (ex/em wavelengths 365/435 nm). 
  
Compound 
Code 
Mitotic Index 
(MI) EC50 (µM) 
Growth Inhibition 
(GI)50 (µM) 
36 N/A N/A 
37 8.90  0.42 4.30  1.13 
38 6.25  0.91 3.70  0.71 
40 9.48  1.10 4.20  0.62 
Dosabulin, 41 3.13  0.32 1.47  0.03 
(R)-Dosabulin N/A N/A 
(S)-Dosabulin 1.23  0.10 0.81  0.37 
 
Table 1. Mitotic arrest EC50 and growth inhibition IC50 values in U2oS for hit compounds. Data displayed as mean  S.D, n = 3; N/A = not 
active. 
